B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug combo shows promise in blood cancer transplant study
Disease control TerminatedThis study tested whether adding the targeted drug inotuzumab ozogamicin before and after a stem cell transplant could help control leukemia and lymphoma. It included 15 people aged 12 to 75 with certain blood cancers. The study was stopped early, but researchers looked at safety…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take aim at Tough-to-Treat leukemia
Disease control TerminatedThis early-phase study tested a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia that returned or didn't respond to standard treatments. The therapy used the patient's own immune cells, modified to target two markers (CD19 and CD20) on leukemi…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental blood cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
CRISPR-Tweaked donor cells take on Hard-to-Treat blood cancers
Disease control TerminatedThis study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aim…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC